pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,922 catalysts · 4,876 phase readout · 2,367 8k filing · 286 earnings · 275 pdufa · 138 phase 2 completion · 64 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,876
  • 8k filing2,367
  • earnings286
  • pdufa275
  • phase 2 completion138
  • phase 1 completion64
  • phase 1 initiation39
  • phase 2 initiation35
  • phase 1 2 completion29
  • phase 0 trial completion22
  • therapy area
    • Oncology122
    • Infectious Disease36
    • Cardiology33
    • Immunology25
    • Dermatology21
    • Pulmonology16
    • Ophthalmology12
    • Women's Health11
    • Pain10

    Week of Apr 27, 2026

    50
    ›Apr 30, 2026phase 1 2 completion87d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

    Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

    full page →M-701 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoNational Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)PEP-CMV

    Therapy area: Oncology. Indication: Ependymoma, Glioma, High-Grade Glioma, Medulloblastoma

    full page →PEP-CMV →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoSichuan Kelun Pharmaceutical Co Ltd — SKB-103 (Phase I/II Trial Initiation)SKB-103

    Therapy area: Oncology. Indication: Solid Tumor

    full page →SKB-103 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoRemeGen Co Ltd — RC-288 (Phase I/II Trial Initiation)RC-288

    Therapy area: Oncology. Indication: Melanoma, Non-Small Cell Lung Cancer, Prostate Cancer, Small-Cell Lung Cancer, Solid Tumor

    full page →RC-288 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoFennec Pharmaceuticals Inc — sodium thiosulfate (Phase I/II Trial Initiation)sodium thiosulfate

    Therapy area: Ear Nose Throat Disorders, Oncology. Indication: Esophageal Cancer, Head And Neck Cancer, Hearing Disorders, Lung Cancer, Malignant Pleural Mesothelioma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor)

    full page →sodium thiosulfate →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoDartsbio Pharmaceutical (Guangdong) Co Ltd — DS-010 (Phase I/II Trial Initiation)DS-010

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Cachexia, Cancer Anorexia-Cachexia Syndrome, Solid Tumor

    full page →DS-010 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoInstitute of Hematology & Blood Diseases Hospital — azacitidine (Phase I/II Trial Initiation)Onureg

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)

    full page →Onureg →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoBeijing Bethune Charitable Foundation — bevacizumab (Phase I/II Trial Initiation)bevacizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoBeijing Eastern Biotech Co Ltd — JY-016 (Phase I/II Trial Initiation)JY-016

    Therapy area: Oncology. Indication: Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Recurrent Head And Neck Squamous Cell Carcinoma, Solid Tumor

    full page →JY-016 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation87d agoCompass Therapeutics Inc — CTX-471 (Phase I/II Trial Initiation)CTX-471

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Glioma, Recurrent Glioblastoma Multiforme (GBM)

    full page →CTX-471 →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →UA-021 →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoCairo University — lidocaine (Phase II Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoVeer Chandra Singh Garhwali Government Medical Science and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Ear Nose Throat Disorders. Indication: Otitis Media

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoUniversity of Benin Teaching Hospital — doxycycline (Phase II Trial Completion)doxycycline ER

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →doxycycline ER →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Dermatology. Indication: Burns

    full page →ayurvedic medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoGandhi Medical College & Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Oncology. Indication: Malignant Neoplasms

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →telitacicept →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoDalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoSmt.B.K.Shah Medical Institute & Research Centre & Dhiraj Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoKSO Corp — undisclosed plant extract (Phase II Trial Completion)undisclosed plant extract

    Therapy area: Genito Urinary System. Indication: Unspecified Genito Urinary Disorders

    full page →undisclosed plant extract →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoThe First Affiliated Hospital of Guangxi Medical University — fospropofol disodium (Phase II Trial Completion)fospropofol disodium

    Therapy area: Central Nervous System. Indication: Sedation

    full page →fospropofol disodium →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

    Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

    full page →amoxicillin →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoQilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)iruplinalkib

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →iruplinalkib →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoTufts Medical Center — phytonadione (Phase II Trial Completion)PHYTONADIONE

    Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

    full page →PHYTONADIONE →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoDanone Research & Innovation — (prebiotics + probiotic + protein blend + micronutrient blend) (Phase II Trial Completion)(prebiotics + probiotic + protein blend + micronutrient blend)

    Therapy area: Central Nervous System, Metabolic Disorders. Indication: Ageing, Unspecified Psychiatric Disorders

    full page →(prebiotics + probiotic + protein blend + micronutrient blend) →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoNational Health and Medical Research Council — docosahexaenoic acid (Phase II Trial Completion)docosahexaenoic acid

    Therapy area: Women's Health. Indication: Labor And Delivery

    full page →docosahexaenoic acid →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoChildren’s Hospital of Chongqing Medical University — iKids-Growth (Phase II Trial Completion)iKids-Growth

    Therapy area: Hormonal Disorders. Indication: Shox Deficiency

    full page →iKids-Growth →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoIntas Pharmaceuticals Ltd — olaparib (Phase II Trial Completion)olaparib

    Therapy area: Oncology. Indication: Breast Cancer, Castration-Resistant Prostate Cancer (CRPC), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peritoneal Cancer, Solid Tumor

    full page →olaparib →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

    Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

    full page →autologous regulatory T cells →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoMerck & Co Inc — pembrolizumab (Phase II Trial Completion)pembrolizumab

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Gliosarcoma

    full page →pembrolizumab →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoAustralasian Gastro-Intestinal Trials Group — valproate sodium (Phase II Trial Completion)VALPROATE SODIUM

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →VALPROATE SODIUM →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

    Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

    full page →dupilumab →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoZhejiang University Hospital One — serplulimab (Phase II Trial Completion)serplulimab

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

    full page →serplulimab →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

    Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

    full page →tulisokibart →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — undisclosed anti-diuretics (Phase II Trial Completion)undisclosed anti-diuretics

    Therapy area: Genito Urinary System. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

    full page →undisclosed anti-diuretics →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Bone Fracture, Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

    Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

    full page →polyphenol-rich cocoa extract →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)aumolertinib mesylate

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer

    full page →aumolertinib mesylate →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoBuck Institute for Research on Aging — Glylo (Phase II Trial Completion)Glylo

    Therapy area: Metabolic Disorders. Indication: Ageing

    full page →Glylo →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoPharmenterprises — XC-243 (Phase II Trial Completion)XC-243

    Therapy area: Genito Urinary System. Indication: Cystitis

    full page →XC-243 →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoSichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital — bupivacaine liposome (Phase II Trial Completion)bupivacaine liposome

    Therapy area: Musculoskeletal Disorders. Indication: Bone Fracture

    full page →bupivacaine liposome →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoMedanta - The Medicity — centhaquine citrate (Phase II Trial Completion)centhaquine citrate

    Therapy area: Cardiovascular, Other Diseases. Indication: Hemorrhagic Shock, Injury, Trauma

    full page →centhaquine citrate →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoDiabete Quebec — insulin (Phase II Trial Completion)insulin

    Therapy area: Metabolic Disorders. Indication: Hyperglycemia, Type 1 Diabetes (Juvenile Diabetes)

    full page →insulin →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoSun Yat-Sen University Hospital 5 — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoXiangyang First People's Hospital — sodium bicarbonate (Phase II Trial Completion)SODIUM BICARBONATE

    Therapy area: Undisclosed. Indication: Unspecified

    full page →SODIUM BICARBONATE →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

    Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

    full page →ozonated oil →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoTaian City Central Hospital — alfentanil (Phase II Trial Completion)alfentanil

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →alfentanil →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoAssaf Harofeh Medical Center — acetaminophen (Phase II Trial Completion)acetaminophen ER

    Therapy area: Central Nervous System. Indication: Pain

    full page →acetaminophen ER →source: globaldata
    ← prev
    page 9 of 159
    next →
    $REGN656.01+0.63%
    $FENC9.9900-1.58%
    $MRK131.07+0.45%
    $COMP11.07+2.69%
    $MRK131.07+0.45%